We provide you with 20 years of free, institutional-grade data for ARVN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARVN. Explore the full financial landscape of ARVN stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-06 | 1655759 | ARVN | 10-Q | Url |
| 2025-05-01 | 1655759 | ARVN | 10-Q | Url |
| 2025-02-11 | 1655759 | ARVN | 10-K | Url |
| 2024-10-30 | 1655759 | ARVN | 10-Q | Url |
| 2024-07-30 | 1655759 | ARVN | 10-Q | Url |
| 2024-05-07 | 1655759 | ARVN | 10-Q | Url |
| 2024-02-27 | 1655759 | ARVN | 10-K | Url |
| 2023-11-07 | 1655759 | ARVN | 10-Q | Url |
| 2023-08-08 | 1655759 | ARVN | 10-Q | Url |
| 2023-05-05 | 1655759 | ARVN | 10-Q | Url |
| 2023-02-23 | 1655759 | ARVN | 10-K | Url |
| 2022-11-09 | 1655759 | ARVN | 10-Q | Url |
| 2022-08-04 | 1655759 | ARVN | 10-Q | Url |
| 2022-05-05 | 1655759 | ARVN | 10-Q | Url |
| 2022-02-28 | 1655759 | ARVN | 10-K | Url |
| 2021-11-03 | 1655759 | ARVN | 10-Q | Url |
| 2021-08-05 | 1655759 | ARVN | 10-Q | Url |
| 2021-05-04 | 1655759 | ARVN | 10-Q | Url |
| 2021-03-01 | 1655759 | ARVN | 10-K | Url |
| 2020-11-05 | 1655759 | ARVN | 10-Q | Url |
| 2020-08-04 | 1655759 | ARVN | 10-Q | Url |
| 2020-04-28 | 1655759 | ARVN | 10-Q | Url |
| 2020-03-16 | 1655759 | ARVN | 10-K | Url |
| 2019-11-04 | 1655759 | ARVN | 10-Q | Url |
| 2019-08-05 | 1655759 | ARVN | 10-Q | Url |
| 2019-05-09 | 1655759 | ARVN | 10-Q | Url |
| 2019-03-26 | 1655759 | ARVN | 10-K | Url |
| 2018-11-14 | 1655759 | ARVN | 10-Q | Url |
| 2018-08-30 | 1655759 | ARVN | S-1 | Url |
Arvinas, Inc(NASDAQ:ARVN) 
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical tri...
Website: http://www.arvinas.com
Founded: 2013
Full Time Employees: 133
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ARVN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.